Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
BlackRock-Led GCC Infrastructure Partnership Targets $30 Billion Investment 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
SOUTH PLAINFIELD, N.J., Sept. 21, 2016 -- Molecular Diagnostics company, Admera Health, (www.admerahealth.com) today announced that its PGxOne™ Plus pharmacogenomics test has been updated to include 25 additional genes, bringing the total number of genes covered to 50.
PGxOne™ Plus results help predict how patients will respond to drug therapy for several therapeutic areas including psychiatry, pain management and cardiology. Leveraging Next Generation Sequencing (NGS) technology, this expanded 50 gene panel interrogates nearly 200 different variants and provides recommendations for over 220 associated drugs. The recommendations include considering alternatives when specific drugs should be avoided, dosage adjustment information when available, use with caution, and normal response expected. The PGxOne™ Plus report also provides information related to drug-to-drug, drug-to-food, drug-to-alcohol and drug-to-laboratory test interactions that are relevant to a patient’s current medications. Thus, test results offer physicians a valuable tool for guiding effective treatment decisions and potentially reducing trial-and-error treatment selection and adverse drug events.
“With this product update we have doubled the number of genes on what was already the most comprehensive pharmacogenomics test on the market. However, only gene variants that have strong clinical evidence associated with drug metabolism, absorption and activity are included in the panel,” stated Guanghui Hu, PhD, President and CEO of Admera.
Dr. Hu went on to elaborate, “As pharmacogenomics testing becomes the standard of care, it is clear that Admera Health is emerging as the leader in this field.”
In addition to pharmacogenomics testing, Admera Health provides genetic testing for the risk assessment and diagnosis of inherited cardiovascular diseases and cancer tumor profiling to guide selection of targeted therapies.
About Admera Health
Admera Health is an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing and digital health. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health fulfills unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
